Biolife Solutions executive sells shares worth $11,442

Mathew Aby J., Executive Vice President and Chief Scientific Officer at BioLife Solutions Inc. (NASDAQ:BLFS), recently sold 569 shares of the company’s common stock. The company, currently valued at approximately $1 billion, maintains strong liquidity with a current ratio of 4.54x, indicating robust financial health. The shares were sold at a price of $20.11 each, totaling approximately $11,442. This transaction, which took place on April 9, 2025, was made under a pre-established Rule 10b5-1 trading plan. Following this sale, Aby holds 309,007 shares directly. The sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock. The stock, currently trading at $21.88, has shown a 28% return over the past year despite recent volatility. According to InvestingPro analysis, which offers 8 additional key insights about BLFS, the stock appears slightly overvalued at current levels.

In other recent news, BioLife Solutions reported strong financial results for the fourth quarter of 2024, with revenue reaching $22.7 million, surpassing analyst estimates of $21.3 million. The company posted a net loss of $2.0 million, which was smaller than the projected loss of $4.4 million. For the full year, BioLife’s revenue totaled $82.3 million, excluding $37.7 million from discontinued operations, with a net loss of $11.4 million. The Cell Processing segment showed significant growth, with a 31% year-over-year increase in revenue for the fourth quarter and a 12% rise for the year. Analysts at H.C. Wainwright raised their price target for BioLife to $30, citing the company’s strong performance and increased revenue projections. KeyBanc Capital Markets maintained an Overweight rating on BioLife, highlighting the company’s focus on its core biopreservation media business and its improved financial position. Benchmark also reiterated a Buy rating, reflecting confidence in BioLife’s continued growth and profitability. Looking ahead, BioLife has issued optimistic guidance for 2025, expecting total revenue to grow between 16% and 20%, with Cell Processing revenue anticipated to rise by 18-21%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.